Johnson & Johnson names former CVS president, CEO as future board chair of consumer health arm

Johnson & Johnson has named former CVS president and CEO Larry Merlo the non-executive chair designate for board of directors of its new consumer health company.

Advertisement

Mr. Merlo will formally assume the role as non-executive chair upon completion of the planned separation of Johnson & Johnson’s consumer line from the rest of its healthcare research and development business, according to an Aug. 24 press release. 

The separation is expected to occur in 2023 with Thibaut Mongon leading the yet-to-be named company as CEO. 

Mr. Melo served as president and CEO of CVS from 2011 until retiring in 2021. Under his leadership, the company completed multiple acquisitions to create a diversified health services company, according to the press release.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The hidden cost of lost clinical time and how leading health systems are responding

Friday, August 7
12:00 PM - 1:00 PM CDT

Presenters: Kassaundra McKnight-Young, Zebra TechnologiesGregory Carras, Zebra TechnologiesJennifer Gene, Levata

Advertisement

Next Up in Disruptors

  • OpenAI signed its first international hospital partnership with Ramat Gan, Israel-based Sheba Medical Center. The deal, according to a July…

  • Microsoft is continuing to hire for health tech roles including a forward deployed AI engineer position tied to its healthcare…

  • Amazon is hiring software and applied-science leaders, AI engineers and a healthcare cybersecurity specialist — the kinds of roles hospital…

Advertisement

Comments are closed.